Standard Dosing Frequency for Tigecycline
Tigecycline (Tygacil), an intravenous glycylcycline antibiotic, is administered every 12 hours for most approved infections, including complicated skin and skin structure infections, complicated intra-abdominal infections, and community-acquired bacterial pneumonia.[1] The typical regimen starts with a 100 mg loading dose, followed by 50 mg maintenance doses every 12 hours.
Adjustments for Specific Infections or Patients
For patients with severe hepatic impairment (Child-Pugh C), reduce maintenance dose to 25 mg every 12 hours after the loading dose.[1] No adjustments are needed for renal impairment. In obese patients (BMI >30 kg/m²), some guidelines suggest weight-based dosing, but frequency remains every 12 hours.[2]
Treatment Duration and Infusion Details
Courses last 5-14 days depending on infection type—shorter for skin infections (5-14 days), longer for pneumonia (7-14 days).[1] Each dose infuses over 30-60 minutes. Tigecycline is not approved for subcutaneous or oral use.
Why Every 12 Hours? Pharmacokinetics
Tigecycline's twice-daily schedule matches its half-life of 27-42 hours and steady-state concentrations achieved after 2-3 days. This allows effective MIC coverage against resistant pathogens like MRSA and Acinetobacter while minimizing toxicity.[3]
Common Side Effects and Monitoring
Nausea (26%) and vomiting (18%) occur frequently; administer antiemetics if needed. Monitor for supersuperinfections and elevated liver enzymes. Avoid in pregnancy due to fetal harm risk.[1]
Alternatives if Twice-Daily Dosing Is Challenging
Switch to once-daily options like vancomycin (for skin infections) or ertapenem (for intra-abdominal), though tigecycline targets multidrug-resistant bugs better in some cases.[4]
[1] Tygacil (tigecycline) prescribing information, Pfizer, 2023. https://labeling.pfizer.com/ShowLabeling.aspx?id=491
[2] IDSA guidelines on skin/soft tissue infections, 2014. https://www.idsociety.org/practice-guideline/skin-and-soft-tissue-infections/
[3] Tigecycline pharmacokinetics review, Clin Pharmacokinet, 2005. https://pubmed.ncbi.nlm.nih.gov/16231958/
[4] Comparison of tigecycline vs alternatives, J Antimicrob Chemother, 2018. https://academic.oup.com/jac/article/73/6/1443/4951334